Search

Displaying results 4571 - 4580 of 7604 in total
  1. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  2. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  3. Drug

    HMI-203

    go.drugbank.com/drugs/DB18520
    Investigational

    HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc.

  4. Drug

    Indoprofen

    go.drugbank.com/drugs/DB08951
    ApprovedWithdrawn

    A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  5. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria[L30543]. … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.

  6. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It will be of major benefit to those patients not responding satisfactorily to diuretics alone.

  7. Drug

    Yeast

    go.drugbank.com/drugs/DB11017
    Approved

    Yeast allergenic extract is used in allergenic testing.

    Categories: Non-Standardized Food Allergenic Extract, Non-Standardized Fungal Allergenic Extract
  8. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery. … Sygen appears to be beneficial in patients with severe spinal cord injury.

  9. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    It is being developed by Exelixis, Inc. … Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

  10. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.